Cargando…

Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis

PURPOSE: We performed a systematic review and a meta-analysis to investigate the successful ablation rate after radioiodine (RAI) administration in patients with differentiated thyroid cancer (DTC) at intermediate-high risk of recurrence. METHODS: A comprehensive literature search of the PubMed, Sco...

Descripción completa

Detalles Bibliográficos
Autores principales: Klain, Michele, Nappi, Carmela, Zampella, Emilia, Cantoni, Valeria, Green, Roberta, Piscopo, Leandra, Volpe, Fabio, Manganelli, Mariarosaria, Caiazzo, Elisa, Petretta, Mario, Schlumberger, Martin, Cuocolo, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566414/
https://www.ncbi.nlm.nih.gov/pubmed/34142215
http://dx.doi.org/10.1007/s00259-021-05440-x
_version_ 1784594005360640000
author Klain, Michele
Nappi, Carmela
Zampella, Emilia
Cantoni, Valeria
Green, Roberta
Piscopo, Leandra
Volpe, Fabio
Manganelli, Mariarosaria
Caiazzo, Elisa
Petretta, Mario
Schlumberger, Martin
Cuocolo, Alberto
author_facet Klain, Michele
Nappi, Carmela
Zampella, Emilia
Cantoni, Valeria
Green, Roberta
Piscopo, Leandra
Volpe, Fabio
Manganelli, Mariarosaria
Caiazzo, Elisa
Petretta, Mario
Schlumberger, Martin
Cuocolo, Alberto
author_sort Klain, Michele
collection PubMed
description PURPOSE: We performed a systematic review and a meta-analysis to investigate the successful ablation rate after radioiodine (RAI) administration in patients with differentiated thyroid cancer (DTC) at intermediate-high risk of recurrence. METHODS: A comprehensive literature search of the PubMed, Scopus, and Web of Science databases was conducted according to the PRISMA statement. RESULTS: The final analysis included 9 studies accounting for 3103 patients at intermediate-high risk of recurrence. In these patients, the successful ablation rates ranged from 51 to 94% with a 71% pooled successful ablation and were higher in intermediate (72%) than in high (52%)-risk patients. Despite the rigorous inclusion standards, a significant heterogeneity among the evaluated studies was observed. Higher administered RAI activities are associated with a lower successful ablation rate in the whole population and in the subgroup of high-risk patients. Furthermore, pooled recurrence rate in intermediate-risk patients achieving successful ablation was only 2% during the subsequent 6.4-year follow-up while the pooled recurrence rate was 14% in patients who did not achieve a successful ablation. CONCLUSION: In a large sample of 3103 patients at intermediate-high risk of persistent/recurrent disease, 71% of patients achieved a successful ablation. In these intermediate-risk patients, the probability of subsequent recurrence is low and most recurrence occurred in those with already abnormal findings at the first control. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05440-x.
format Online
Article
Text
id pubmed-8566414
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85664142021-11-15 Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis Klain, Michele Nappi, Carmela Zampella, Emilia Cantoni, Valeria Green, Roberta Piscopo, Leandra Volpe, Fabio Manganelli, Mariarosaria Caiazzo, Elisa Petretta, Mario Schlumberger, Martin Cuocolo, Alberto Eur J Nucl Med Mol Imaging Original Article PURPOSE: We performed a systematic review and a meta-analysis to investigate the successful ablation rate after radioiodine (RAI) administration in patients with differentiated thyroid cancer (DTC) at intermediate-high risk of recurrence. METHODS: A comprehensive literature search of the PubMed, Scopus, and Web of Science databases was conducted according to the PRISMA statement. RESULTS: The final analysis included 9 studies accounting for 3103 patients at intermediate-high risk of recurrence. In these patients, the successful ablation rates ranged from 51 to 94% with a 71% pooled successful ablation and were higher in intermediate (72%) than in high (52%)-risk patients. Despite the rigorous inclusion standards, a significant heterogeneity among the evaluated studies was observed. Higher administered RAI activities are associated with a lower successful ablation rate in the whole population and in the subgroup of high-risk patients. Furthermore, pooled recurrence rate in intermediate-risk patients achieving successful ablation was only 2% during the subsequent 6.4-year follow-up while the pooled recurrence rate was 14% in patients who did not achieve a successful ablation. CONCLUSION: In a large sample of 3103 patients at intermediate-high risk of persistent/recurrent disease, 71% of patients achieved a successful ablation. In these intermediate-risk patients, the probability of subsequent recurrence is low and most recurrence occurred in those with already abnormal findings at the first control. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05440-x. Springer Berlin Heidelberg 2021-06-18 2021 /pmc/articles/PMC8566414/ /pubmed/34142215 http://dx.doi.org/10.1007/s00259-021-05440-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Klain, Michele
Nappi, Carmela
Zampella, Emilia
Cantoni, Valeria
Green, Roberta
Piscopo, Leandra
Volpe, Fabio
Manganelli, Mariarosaria
Caiazzo, Elisa
Petretta, Mario
Schlumberger, Martin
Cuocolo, Alberto
Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
title Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
title_full Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
title_fullStr Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
title_full_unstemmed Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
title_short Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
title_sort ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566414/
https://www.ncbi.nlm.nih.gov/pubmed/34142215
http://dx.doi.org/10.1007/s00259-021-05440-x
work_keys_str_mv AT klainmichele ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT nappicarmela ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT zampellaemilia ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT cantonivaleria ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT greenroberta ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT piscopoleandra ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT volpefabio ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT manganellimariarosaria ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT caiazzoelisa ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT petrettamario ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT schlumbergermartin ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis
AT cuocoloalberto ablationrateafterradioactiveiodinetherapyinpatientswithdifferentiatedthyroidcanceratintermediateorhighriskofrecurrenceasystematicreviewandametaanalysis